JAC Advance Access published online on January 6, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg074
© 2003 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original article
1 Department of Microbiology
and Infectious Diseases, Women's and Children's
Hospital,
72 King William Road, North Adelaide, SA 5006, Australia
* Corresponding author. E-mail: bellj{at}mail.wch.sa.gov.au.
Received 28 July 2002
; revised 12 September 2002
; accepted 4 November 2002
Multiresistance to antimicrobial agents is common in
staphylococci and pneumococci isolates in the Western Pacific region.
The activity of linezolid, a new oxazolidinone, was evaluated against
a spectrum of Gram-positive species collected in the region. Eighteen
laboratories from six countries in the Western Pacific examined
the linezolid susceptibility of 2143 clinical isolates of Staphylococcus
aureus, coagulase-negative staphylococci (CoNS) and Enterococcus spp. using
broth microdilution or disc diffusion methodology. For Streptococcus
pneumoniae (n = 351)
and other streptococci (n = 83), Etest
(AB Biodisk, Solna, Sweden) strips were used. Results were compared
with other common and important antimicrobials. Linezolid-resistant strains
were not detected among streptococci or staphylococci, including
a significant proportion of S. aureus strains that
were multiresistant. Almost all enterococci, including
14 vancomycin-resistant Enterococcus faecium,
were linezolid susceptible. A small proportion of enterococci (0.8%)
were intermediate to linezolid, and one strain of Enterococcus
faecalis had a zone diameter of 20 mm (resistant). The linezolid
MIC ranges (MIC90) of those strains tested by
broth microdilution or Etest were: 1-4 mg/L (2 mg/L) for S. aureus, 0.5-4 mg/L (2 mg/L) for CoNS,
0.5-4 mg/L (2 mg/L) for Enterococcus spp.,
0.12-2 mg/L (1 mg/L) for S. pneumoniae and 0.25-2
mg/L (1 mg/L) for Streptococcus spp. There was
no difference in linezolid susceptibility between countries or between
multiresistant and susceptible strains of each species monitored.
Keywords: linezolid, Western Pacific region, ZAPS
Multicentre evaluation of the in vitro activity
of linezolid in the Western Pacific
2 Buffalo Clinical Research Center,
Buffalo, NY
3 The Jones Group/JMI Laboratories,
North Liberty, IA; Tufts
University School of Medicine, Boston, MA, USA
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. N. Jones, M. G. Stilwell, P. A. Hogan, and D. J. Sheehan Activity of Linezolid against 3,251 Strains of Uncommonly Isolated Gram-Positive Organisms: Report from the SENTRY Antimicrobial Surveillance Program Antimicrob. Agents Chemother., April 1, 2007; 51(4): 1491 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kelly, J. Collins, M. Davin, C. Gowing, and P. G. Murphy Linezolid resistance in coagulase-negative staphylococci1 J. Antimicrob. Chemother., October 1, 2006; 58(4): 898 - 899. [Full Text] [PDF]
|
|
|
|
|
|
R. N. Jones, J. E. Ross, T. R. Fritsche, and H. S. Sader Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations J. Antimicrob. Chemother., February 1, 2006; 57(2): 279 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Phillips, M. Casewell, T. Cox, B. De Groot, C. Friis, R. Jones, C. Nightingale, R. Preston, and J. Waddell Antibiotic use in animals J. Antimicrob. Chemother., May 1, 2004; 53(5): 885 - 885. [Full Text] [PDF]
|
|